Abstract. Glioma is an aggressive malignancy with limited effective treatment and poor prognosis. Therefore, the identification of novel prognostic markers and effective therapeutic targets is important for the treatment of human glioma. TIP30 is a tumor suppressor involved in the regulation of numerous cellular processes, including tumor cell growth, metastasis, and angiogenesis in various human cancers. The present study investigated whether Tat-interacting protein (TIP)30 was able to regulate tumorigenesis and predict the clinical outcome of patients with glioma. A total of 92 human glioma tissue samples and 10 normal brain tissue samples were examined by immunostaining. The results indicated that the expression levels of TIP30 significantly decreased in glioma tissue samples. as compared with normal brain tissue samples. Furthermore, TIP30 expression was inversely correlated with tumor histological classification, pathological grade, tumor size, and epidermal growth factor receptor (EGFR) expression; however, no association was detected between TIP30 expression and patient age and gender. In addition, patients with positive TIP30 expression exhibited significantly longer median overall survival rates, as compared with those with negative TIP30 expression. In vitro experiments revealed that upregulation of TIP30 expression by lentiviral vector transfection inhibited cell growth and induced cell apoptosis, as determined by MTT assay and Annexin V-fluorescein isothiocyanate staining, respectively. In addition, TIP30 expression markedly attenuated cell migration and invasion, as determined by wound healing and transwell assays. Upregulation of TIP30 expression in glioma cells decreased the expression levels of EGFR and its associated downstream molecules phosphorylated extracellular signal-regulated kinases (ERK) and phosphorylated AKT, as determined by western blot analysis. The results of the present study indicated that TIP30 may suppress oncogenesis and glioma progression, thereby improving the prognosis of patients with glioma. Therefore, TIP30 may prove useful as a prognostic biomarker, and as a potential target for glioma therapy.
Introduction
Glioma is the most common type of malignant intracranial tumor, accounting for ~50% of all intracranial tumors (1) . Glioma is the second most common cause of cancer-associated mortality in patients ≤34 years old, and the third most common cause in patients between 35 and 54 years old (2) . Glioma is characterized by intense cell proliferation, diffuse infiltration, resistance to chemotherapy, high mortality, high recurrence, and poor clinical prognosis. Surgery and chemotherapy remain the standard treatments (3); however, prognosis is poor, and patients usually have a short survival time attributed to the aggressive nature of glioma. Therefore, identifying novel prognostic markers, carcinogenic pathways, and therapeutic targets is crucial for the treatment of glioma.
Tat-interacting protein (TIP)30 is a 30kD molecule, which was initially identified as a tumor suppressor of small cell lung cancer (4) . As a serine/threonine kinase and cofactor, TIP30 exhibits intrinsic kinase activity, and is able to phosphorylate the C-terminal domain of RNA polymerase II and potentiate human immunodeficiency virus transcription by binding to Tat (5, 6) . TIP30 is widely expressed in normal human tissues, such as the heart, brain, lung, kidney, and pancreas, however its expression levels are decreased in numerous cancers such as breast cancer, lung cancer, liver cancer, gastric cancer, and colorectal cancer (7) (8) (9) (10) (11) . Previous studies have demonstrated that TIP30 inhibits the development of numerous types of tumor by suppressing tumor cell growth, promoting cell apoptosis, inhibiting tumor angiogenesis, impairing DNA repair, regulating tumor cell glucose tolerance, and inhibiting nuclear transportation (12) (13) (14) (15) (16) . However, the role of TIP30 in human glioma development remains to be elucidated.
Epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor of the ErbB family, which activates intracellular mitogenic signaling and other (19) . The present study aimed to investigate the expression and clinical significance of TIP30 in glioma tumors, as well as the correlation between TIP30 and EGFR.
Overexpression of TIP30 inhibits the growth and invasion of glioma cells

Materials and methods
Tissue samples and histology. Paraffin-embedded cancerous tissue samples of 92 patients with glioma who underwent surgery between 2006 and 2011, were obtained from the Department of Cerebral Surgery of Nanfang Hospital (Guangzhou, China). The patients had not undergone chemotherapy or radiotherapy prior to surgery. Patient characteristics are shown in Table I . The glioma tissue samples were histologically classified by pathologists according to the World Health Organization criteria (20) . A total of 10 normal brain tissue samples (3 females, 7 males; average age, 25.4 years old) were obtained from patients undergoing surgery for epilepsy (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) in order to serve as a control. All patients provided written informed consent, and all experiments were approved by the Research Ethics Committee of Nanfang Hospital (Guangzhou, China).
Immunohistochemistry (IHC).
Slides containing the glioma tissue samples were deparaffinized and hydrated, prior to antigen retrieval and endogenous peroxidase clearance (Beyotime Institute of Biotechnology, Shanghai, China). Heat-induced antigen retrieval was performed in citrate buffer for 2 min at 100˚C. Endogenous peroxidase activity and nonspecific antigens were blocked with peroxidase blocking reagent containing 3% hydrogen peroxide and serum. The samples were then incubated with polyclonal antibodies targeting TIP30 (1:50; cat. no. ab22841; Abcam, Cambridge, UK) and EGFR (1:400; cat. no. 1902-1; Epitomics, Burlingame, CA, USA) at 4˚C overnight. IHC images were captured using an Olympus fluorescence microscope (Olympus CKX41; Olympus Corporation, Tokyo, Japan) equipped with a camera.
The glioma tissue samples were reviewed by two pathologists. Staining was evaluated by measuring the intensity and percentage of positive cells in each sample. TIP30 staining was predominantly located in the cytoplasm, whereas EGFR staining was predominantly located in the cell membrane. Staining intensity was classified as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong). An area of staining intensity was defined as 0 if <10%, 1 if 10-30%, 2 if 31-60%, and 3 if >60%. The staining percentage and intensity scores were multiplied in order to obtain a total score, of which >2 indicated a positive result.
Survival follow-up. The patients were followed-up by telephone until February, 9 2012. The median overall survival (mOS) rates were calculated from the day of surgery until the follow-up deadline, or until the patients succumbed to their disease. RT-qPCR. RT-qPCR was used to quantify TIP30 mRNA expression. Total RNA from all cells were extracted using TRIzol reagent (Takara Bio, Inc., Otsu, Japan) and reverse transcribed to cDNA using the PrimeScript kit (Takara Bio, Inc.) according to the manufacturer's instructions. RT-qPCR was performed using Fast SYBR Green I kit (Takara Bio, Inc.) and an ABI 7500 thermal cycler (Applied Bioscience; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was used. The following primers were used: TIP30 sense, 5'-AGAAACCGGCAGAGTGCTCTTA-3', antisense, 5'-GTACCCAGGCAACAGAATCCA-3'; and β-actin sense, 5'-TGGCACCCAGCACAATGAA-3', and antisense, 5'-CTAAGTCATAGTCCGCCTAGAAGCA-3'. PCR cycling conditions were as follows: Once cycle of 95˚C for 30 sec, followed by 40 cycles of 95˚C for 5 sec, 60˚C for 20 sec, and 65˚C for 15 sec. Specificity of amplification products was confirmed by melting curve analysis. Each sample was assayed in triplicate in independent reactions. The expression of RNA was calculated using the 2 -ΔΔCt method.
Cell
Western blotting. Briefly, the cells were washed twice with ice-cold phosphate-buffered saline and lysed in 250 ml radioimmunoprecipitation assay buffer containing protease inhibitors (Beyotime Institute of Biotechnology). The protein samples were collected from the cell lysates, and the protein content of the supernatants was determined with a Bradford assay (Beyotime Institute of Biotechnology), using a protein assay dye reagent and bovine serum albumin (Invitrogen Life Technologies) as the standard. For each blot an internal standard was loaded alongside the protein samples (40 µg), and the samples were separated using self-cast stacking 10% resolving gels in Tris-glycine running buffer. In transfer buffer, the blots were transferred wet onto polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA) for 90 min at 120 V. Membranes were incubated with 1% fat-free milk for 1 h at room temperature with agitation, for blocking. Membranes were subsequently washed two times for 10 min in tris-buffered saline containing Tween (TBST) and then incubated with primary antibody overnight (16 h) at 4˚C. The primary antibodies were as follows: Anti-TIP30 (1:1,000; cat no. ab22841; Abcam), anti-EGFR (1:2,000, cat. no. 1902-1; Epitomics), anti-pAKT (1:1,000, cat. no. 5056, Cell Signaling Technology Inc.), anti-pERK (1:1,000, cat. no. 4370P, Cell Signaling Technology Inc.). The following morning, the membranes were washed a further two times (10 min) in TBST, and incubated with a secondary antibody (HRP-labeled goat anti-rabbit IgG; 1:1000; cat. no. A0208; Beyotime Institute of Biotechnology) in 1% fat-free milk for 60 min at room temperature. Following a final two washes (10 min) in TBST, the membranes were visualized using Odyssey Infrared Laser-Imaging system (LI-COR Biosciences, Lincoln, NE, USA).
Cell proliferation assay. An MTT assay was used to evaluate cell proliferation. Cells were seeded in 96-well plates (1x10 3 cells/well) and observed for 7 days. A total of 10 µl MTT (Beyotime Institute of Biotechnology) was added to each well and incubated at 37˚C for 4 h. Subsequently, 150 µl dimethyl sulfoxide (Beyotime Institute of Biotechnology) was added to the cells and the cells were agitated for 15 min. The optical density values of each well were measured at a wavelength of 490 nm (Thermo Fisher Scientific, Inc.). All experiments were performed in triplicate.
Cell apoptosis assay. The U87 cells (1x10 5 ) were harvested through trypsinization (Invitrogen Life Technologies) and resuspended in Annexin V-fluorescein isothiocyanate (FITC) binding buffer (Beyotime Institute of Biotechnology). The Annexin V-FITC solution was then incubated at room temperature in the dark for 10 min. The solution was centrifuged at 1,000 x g for 5 min at 4˚C and the supernatant was discarded. Annexin V-FITC binding buffer and propidium iodide (Beyotime Institute of Biotechnology) were added to the U87 cells, and fluorescence-activated cell sorting analysis was performed following 1 h using a FACSCalibur (BD Biosciences, San Jose, CA, USA).
Cell migration and invasion assay. The U87 cells (1x10 5 ) were seeded in a 6-well plate and a wound was made using a plastic pipette tip. Images were captured at 0, 18 and 36 h. Transwell chambers containing polycarbonate membrane filters (8 µm pore size; BD Biosciences) were coated with Matrigel. A total of 0.2 ml DMEM was added to the upper chamber containing the glioma cells, and 0.6 ml complete medium supplemented with 15% FBS was added to the lower chamber. Following a 48 h time period, the cells that had migrated through the membranes were fixed in paraformaldehyde and stained with 0.1% crystal violet (Beyotime Institute of Biotechnology). The images of five randomly selected fields were captured using a microscope (Olympus CKX41, Olympus Corporation) in order to calculate the number of cells that had successfully invaded the Matrigel (BD Biosciences).
Statistical analysis. SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA) was used to carry out all statistical analyses. Pearson χ 2 tests were used to evaluate the expression levels of TIP30 in the glioma tissue samples, as compared with normal brain tissue samples, and to determine the association between TIP30 expression and clinicopathological features. The overall survival time was analyzed using the Kaplan-Meier method, and a Cox regression model was used for multvariate analysis of the factors influencing mOS. All other in vitro assay results were presented as the mean ± standard deviation, and a Student's t-test was used to determine statistically significant differences between groups. P<0.05 was considered to indicate a statistically significant difference. All statistical tests were two-way analyses.
Results
Expression levels of TIP30 and EGFR and their correlation with the clinicopathological features of glioma. IHC was performed in order to assess the expression of TIP30 in glioma tissue samples, as compared with normal brain tissue samples. TIP30-positive immunostaining was present in 90% (9/10) of normal brain tissue samples, which was significantly higher than the 54.3% (50/92) present in glioma tissue samples (P= 0.03). Conversely, positive expression of EGFR in glioma tissue samples was significantly higher, as compared with normal brain tissue samples (57.6 and 20.0%, respectively; P= 0.04) (Table II) (Figs. 1A and B) .
There was no significant correlation between TIP30 expression, and age and gender. However, TIP30 expression was inversely correlated with histological classification, pathological grade, and tumor size. Conversely, EGFR expression was positively correlated with histological classification, pathological grade, and tumor size (Table II) . Following recent research on TIP30-induced regulation of EGFR degradation in normal and cancerous cells (19) , the correlation between TIP30 and EGFR expression was further investigated using the Spearman's Rank Correlation Coefficient analysis. Notably, the protein expression of TIP30 was inversely correlated with the protein expression of EGFR in glioma tissue samples (Table III) .
The mOS time of all patients was ~23.7 months. Using the Kaplan-Meier method, previous determined factors including glioblastoma multiforme histology and pathological grades III-IV were shown to be associated with a shorter mOS time. Notably, patients with TIP30-positive expression or EGFR-negative expression exhibited significantly longer mOS times (26.4 and 27.0 months, respectively), as compared with those with TIP30-negative or EGFR-positive expression (26.4 and 27.0, vs. 20.6 and 21.3 months, respectively; P<0.05; Fig. 1C and Table IV ). To determine whether TIP30 expression was an independent predictor of patient mOS, a Cox regression model was used for the multivariate analysis of all of the factors influencing mOS. The results indicate that TIP30 expression, alongside histological classification and pathological grade, were independent prognostic factors for cancer-specific mOS (Table V) .
Overexpression of TIP30 inhibits glioma cell growth.
In order to elucidate the functional role of TIP30 in glioma cells, TIP30 was overexpressed in U87 glioma cells, which previously possessed low expression levels of TIP30 (8), using a lentivirus encoding TIP30 cDNA (LV-TIP30). As determined by RT-qPCR and western blotting, the cells in the LV-TIP30 group stably overexpressed TIP30 at both the mRNA and protein level, as compared with the mock treatment group (Mock) or vector-transfected group (LV-Con) ( Fig. 2A  and 2B ). As demonstrated by the cell proliferation assay, upregulation of TIP30 markedly inhibited the proliferation of TIP30-transfected cells, as compared with the cells from the Mock and LV-Con groups (Fig. 2C) . Annexin V-FITC staining demonstrated that the percentage of early apoptotic cells was significantly increased in the LV-TIP30 U87 cells, as compared with the LV-Con and mock U87 cells (36.2±3.88, 0.4±0.13 and 0.84±0.16%, respectively; P<0.05). These results indicate that TIP30-induced U87 glioma cell growth inhibition is likely due to the activation of early apoptosis ( Fig. 2D and 2E) .
Overexpression of TIP30 inhibits invasion and migration of glioma cells.
As determined by the wound healing assay, the Table II . Correlation between the protein expression of Tat-interacting protein (TIP)30 and epidermal growth factor receptor (EGFR), and the clinicopathological features of patients with glioma. U87 glioma cells infected with LV-TIP30 migrated and filled the wound less rapidly, as compared with the LV-Con U87 glioma cells (Fig. 3A) . Concordant with the wound healing assay results, the number of LV-TIP30 U87 glioma cells that invaded the Matrigel was significantly lower, as compared with the LV-Con group (62.2±8.3, vs. 190.4±16.0 cells per field; Fig. 3B and C). These data indicate that TIP30 may inhibit the invasion and migration of U87 glioma cells.
TIP30 EGFR -----------------------------------------------------------------------------------------------------------------------------------------------------
TIP30 (no. of cases) --------------------------------------------
U87 glioma cell infection with LV-TIP30 induces downregulation of EGFR/phosphorylated (p)ERK/pAKT expression.
EGFR expression is negatively correlated with TIP30 expression in glioma tissue samples, as previously mentioned. In addition, the overexpression of TIP30 in U87 glioma cells significantly downregulated the expression levels of EGFR in vitro, as determined by western blotting. Furthermore, the expression levels of pERK and pAKT were also markedly decreased following TIP30 overexpression (Fig. 4) . These results suggest that upregulation of TIP30 may negatively regulate the expression of EGFR and its downstream signal pathways, resulting in the inhibition of tumor growth and invasion.
Discussion
To our knowledge, the present study is the first to report that TIP30 expression is markedly decreased in glioma tissue samples. The results demonstrated that TIP30 expression is inversely correlated with tumor histological classification, pathological grade, tumor burden, and EGFR expression. Reduced TIP30 expression also significantly affected the clinical outcome of patients with glioma, and predicted poor survival rate. Furthermore, the results indicated that TIP30 was an independent prognostic factor for the survival time of patients with glioma. In vitro experiments demonstrated that the overexpression of TIP30 is able to inhibit glioma cell growth, induce tumor cell apoptosis, and suppress tumor cell migration and invasion. In addition, overexpression of TIP30 
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in U87 glioma cells was able to induce the downregulation of EGFR expression and its downstream signaling components. These results indicated that TIP30 may regulate anti-carcinogenic activities in glioma cells. The majority of gliomas are incurable and patient prognosis is usually poor. Histological classification and pathological grades are widely used as prognostic factors for patients with glioma. However, patients with similar histological or pathological grades may have different clinical outcomes. It is therefore necessary to identify novel prognostic and predictive markers. The results of the present study demonstrated that loss of TIP30 expression in patients with glioma was correlated with poor mOS. TIP30 expression, as well as histological classification and pathological grading, were shown to be successful independent prognostic factors for predicting the clinical outcome of patients with glioma. TIP30 expression was also markedly decreased in glioma tissue samples, as compared with normal brain tissue samples. These data indicated that loss of TIP30 expression may be involved in the development and progression of gliomas; however the intrinsic mechanism underlying the association between TIP30 and glioma has yet to be elucidated.
In vitro studies demonstrated that overexpression of TIP30 is able to inhibit glioma cell growth, which may be associated with TIP30-induced cell apoptosis. TIP30 was also shown to inhibit tumor cell migration and invasion in wounds and Matrigel in vitro. TIP30 is a putative tumor suppressor gene, which can downregulate genes associated with cell proliferation, apoptosis, and metastasis, thereby exhibiting anti-tumor effects in cancer (6). TIP30 is able to induce cellular apoptosis by elevating the expression levels of B cell lymphoma 2 (Bcl-2)-associated agonist of cell death, Siva, NM23-H2, Bcl-2-associated protein X, and p53, promoting mitochondrial cytochrome c release, and by downregulating the expression levels of anti-apoptotic genes such as Bcl-xL and c-myc (5, 21) . In addition, TIP30 inhibits the expression levels of tumor metastasis-associated genes, such as osteopontin (22) and calcium adhesion proteins in liver cancer (23) . These results indicated that TIP30 may exhibit anti-tumor effects in glioma; however, the mechanism underlying TIP30 function in glioma remains to be elucidated. 
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EGFR is commonly overexpressed and amplified in gliomas, which contributes to the uncontrolled proliferation and invasion of glioma cells (24) . The results of the present study indicated that patients with glioma with positive EGFR expression exhibited significantly shorter mOS times, as compared with those with negative EGFR expression. Notably, the clinical data of the present study also demonstrated the expression levels of TIP30 were inversely correlated with the expression levels of EGFR in glioma tissue samples. Further in vitro studies demonstrated that the overexpression of TIP30 in glioma cells decreased the expression levels of EGFR, and its downstream signaling molecules. The correlation between TIP30 and EGFR has been the subject of numerous studies. Zhang et al (25) demonstrated that TIP30 knockout mice exhibited a higher incidence of spontaneous mammary tumors, which was correlated with the upregulation of EGFR and its intracellular signaling pathways pAKT and pERK. Zhang et al (26) also identified a protein complex consisting of TIP30, acyl-coenzyme A synthetase long-chain family member 4, and endophilin B1 that was able to promote the fusion of endocytic vesicles with Rab5a vesicles, thus promoting the exit of EGFR-EGF, acceleration of EGFR degradation, and termination of downstream signal transduction pathways such as phosphoinositide 3-kinase/ERK. The results of previous studies combined with those of the present study led to the hypothesis that TIP30 may exert its role, at least partly, through the regulation of EGFR and its downstream signaling pathways, resulting in the inhibition of tumor cell growth and metastasis in gliomas. However, the molecular mechanism underlying the interaction between TIP30 and EGFR in gliomas requires further research.
In conclusion, the results of the present study demonstrated that the expression of TIP30 is markedly decreased in glioma tissue samples. TIP30 may function as a tumor suppressor gene and act as a predictive factor for the prognosis of patients with glioma. Given that the overexpression of TIP30 in glioma cells inhibits tumor proliferation, metastasis and migration, TIP30 may be a potent therapeutic target for patients with glioma.
